The Syndax team is comprised of senior executives with extensive experience in oncology and leading the field of epigenetics.

Michael A. Metzger
President and Chief Operating Officer

Michael A. Metzger has served as our President and Chief Operating Officer since May 2015. Prior to joining Syndax, Mr. Metzger was President, Chief Executive Officer and a Member of the Board of Directors of Regado Biosciences, where he oversaw the company's successful merger with Tobira Therapeutics in 2015. Previously, Mr. Metzger served as Executive Vice President and Chief Operating Officer at Mersana Therapeutics, a privately held biopharmaceutical company developing novel immunoconjugate therapies for cancer, from 2011 to 2013, and in senior business development positions including leading Mergers and Acquisitions at Forest Laboratories, Inc. from 2006 to 2011. Prior to Forest, Mr. Metzger served as Vice President Corporate Development at Onconova Therapeutics, Inc., from 2001 until 2006, and was a Managing Director at Mesa Partners, Inc., a venture capital firm, from 1997 to 2001. Mr. Metzger holds a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business.